<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Triamcinolone - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../sickbay-shared.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Triamcinolone</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Derm / ENT / Eye / Topicals</div>
      <h1>Triamcinolone</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Triamcinolone 0.1% Cream</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Inflammatory dermatoses (eczema, atopic dermatitis, contact dermatitis, psoriasis)</strong>
            <ul>
              <li>Apply thin film to affected area 2–3 times daily</li>
              <li>Once improvement seen, reduce frequency to once or twice daily or as needed</li>
              <li>0.1% cream is a medium-potency topical corticosteroid</li>
            </ul>
          </li>
          <li><strong>Duration of use</strong>
            <ul>
              <li>Use for shortest duration necessary to control symptoms (typically 1–2 weeks for acute flares)</li>
              <li>Reassess if no improvement after 2 weeks or if worsening</li>
              <li>Avoid prolonged continuous use to minimize risk of skin atrophy and HPA axis suppression</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Inflammatory and pruritic dermatoses responsive to topical corticosteroids</li>
          <li>Eczema/atopic dermatitis flares</li>
          <li>Contact dermatitis (allergic or irritant)</li>
          <li>Seborrheic dermatitis</li>
          <li>Psoriasis (limited areas; not as first-line for extensive disease)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Untreated bacterial, viral, or fungal skin infections (can worsen infection; treat infection first or use with appropriate antimicrobial)</li>
          <li>Rosacea, acne vulgaris, perioral dermatitis (may worsen)</li>
          <li>Avoid use on face, groin, and axillae if possible (higher risk of skin atrophy and absorption); if needed, use for shortest duration and lower potency when feasible</li>
          <li>Open wounds or broken skin (absorption and delayed healing)</li>
          <li>Prolonged use or large surface area application: risk of systemic absorption and HPA axis suppression</li>
          <li>Children: use lower potency and limit duration; increased systemic absorption risk</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Local: burning, itching, dryness at application site (usually mild and transient)</li>
          <li>Skin atrophy (thinning), striae, telangiectasia (with prolonged use or high-potency formulations)</li>
          <li>Hypopigmentation (reversible after discontinuation)</li>
          <li>Acneiform eruptions, perioral dermatitis</li>
          <li>Secondary infection (bacterial or fungal)</li>
          <li>Systemic effects (rare with appropriate topical use): HPA axis suppression, Cushing's syndrome, hyperglycemia (with prolonged use over large areas)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>Topical cream: apply thin film to clean, dry affected area; gently rub in</li>
          <li>Wash hands before and after application (unless treating hands)</li>
          <li>Do not apply to face or intertriginous areas (groin, axillae) unless directed and for shortest duration</li>
          <li>Avoid occlusive dressings unless specifically indicated (increases absorption and potency)</li>
          <li>Do not use on open wounds or near eyes</li>
          <li>Counsel: use as directed, do not apply more frequently or for longer than recommended</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response: reduction in erythema, scaling, pruritus</li>
          <li>Signs of skin atrophy: thinning, striae, telangiectasia (especially with prolonged use)</li>
          <li>Secondary infection: worsening redness, pustules, increased pain or drainage</li>
          <li>If prolonged use or large area coverage: monitor for systemic effects (hyperglycemia, signs of Cushing's)</li>
          <li>Reassess diagnosis if no improvement after 2 weeks of appropriate therapy</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Confirm dermatitis/inflammatory condition before use—avoid if infection suspected (consider swab/culture if available or evacuate if uncertain and severe)</li>
          <li>If infection present (impetigo, cellulitis, fungal): treat infection first with appropriate antimicrobial; may use triamcinolone concurrently only if inflammatory component significant and under medical guidance</li>
          <li>For facial rashes or perioral dermatitis: avoid medium-potency steroids; consider lower potency or non-steroidal options if available</li>
          <li>Document area treated, frequency, and duration; educate on taper/discontinuation once improved</li>
          <li>If rash spreads or worsens despite treatment, reassess for alternate diagnosis (drug reaction, systemic process) and consider evacuation</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (triamcinolone acetonide cream): <a href="https://pdf.hres.ca/dpd_pm/00066353.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00066353.PDF</a></li>
          <li>DermNet NZ (topical corticosteroid use): <a href="https://dermnetnz.org/topics/topical-corticosteroids" target="_blank" rel="noopener">https://dermnetnz.org/topics/topical-corticosteroids</a></li>
          <li>Medscape reference (triamcinolone topical): <a href="https://reference.medscape.com/drug/kenalog-aristocort-triamcinolone-topical-343655" target="_blank" rel="noopener">https://reference.medscape.com/drug/kenalog-aristocort-triamcinolone-topical-343655</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
